Ardelyx vs Phathom Pharmaceuticals
ARDX and PHAT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDX and PHAT compare
Ardelyx is the larger company, worth 1.6 times as much as Phathom Pharmaceuticals ($770M against $493M).
Phathom Pharmaceuticals grew revenue faster over the last twelve months (86.8% versus 16.8% for Ardelyx).
Ardelyx keeps more of each dollar of sales as profit, with a net margin of −12.4% compared with −30.2% at Phathom Pharmaceuticals.
Ardelyx scores higher on the StockData Score (9 against 4 for Phathom Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDX | PHAT |
|---|---|---|
| Size and price | ||
| Market cap | $770M | $493M |
| Share price | $3.09 | $6.06 |
| Change, 1 year | −48.8% | −58.5% |
| Change, 5 years | 209% | −69.8% |
| Beta (5Y) | 0.95 | 1.63 |
| Employees | 489 | 371 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 2 (better) | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 1.8× |
| P/B | 5.2× | – |
| FCF yield | −2.3% (better) | −4.3% |
| Fair value | $7.50 | – |
| Margin of safety | 58.8% | – |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 86.8% (better) |
| Revenue growth, 5Y average | 122% | – |
| Profitability | ||
| Gross margin | 94.4% (better) | 80.7% |
| Operating margin | −7.9% (better) | −9.3% |
| Net margin | −12.4% (better) | −30.2% |
| FCF margin | −4.0% (better) | −7.7% |
| Return on equity | −38.6% | – |
| Financial health | ||
| Interest coverage | −1.6× | −0.4× (better) |
| Current ratio | 3.34 (better) | 1.76 |
| Altman Z-score | −0.13 (better) | −4.83 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.2% | 88.7% |
| Held by insiders | 6.9% | 12.2% |
| Insider net buying, 12 months | −$1.9M | $0 (better) |
| Short interest, % of float | 12.6% | 12.9% |
Go deeper
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
- PHAT stock overview
- PHAT income statement
- PHAT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.